Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-03-14
Intellia Therapeutics, Inc.
Intellia Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR gene-editing therapies for hereditary angioedema, ATTR amyloidosis and other severe diseases.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof-gated upside in one-time gene editing
The setup is attractive because a successful HAE launch could turn a clinical platform into a commercial rare-disease franchise from a still-restrained valuation. The path is real, but it is dominated by one pivotal readout and the need to rebuild regulatory trust in ATTR.

Analysis

Thesis
If HAELO succeeds, Intellia can jump from collaboration revenue to a real rare-disease franchise led by a one-time HAE therapy, with ATTR recovery and smarter contracting adding upside; the bet is less on AI software and more on turning regulated biological proof into durable product economics.
Last Economy Alignment
Low software commoditization exposure helps: value sits in IP, clinical evidence, regulatory trust and treatment workflow, not seats or UI. AI can speed design and monitoring, but biology, safety and FDA trust remain the real gates.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
6.2x (from 5 most recent analyses)
Reasoning
The upside comes from crossing one hard gate: positive HAELO data would shift Intellia from being valued mainly as a research platform to being valued as a launch-stage rare-disease company. I keep the outcome below elite biotech-platform cases because ATTR still needs trust rebuilt, the first commercial base is narrow, and financing likely dilutes part of the operating win.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a proof-gated biotech. A positive HAELO readout can unlock a real commercial rerating, but a miss or ambiguous safety signal resets the core thesis. Even with a win, Intellia still must navigate FDA review, payer acceptance for irreversible editing, ATTR restart credibility and financing that can trim per-share upside.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.26
They are not selling AI-generated advice; they are trying to own the regulated proof that a one-time gene edit works safely in people. If that proof lands, each treated patient and follow-up dataset strengthens trust with doctors and payers, but one bad safety signal can still break the flywheel.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.45
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case